0001209191-22-047903.txt : 20220829
0001209191-22-047903.hdr.sgml : 20220829
20220829174610
ACCESSION NUMBER: 0001209191-22-047903
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220825
FILED AS OF DATE: 20220829
DATE AS OF CHANGE: 20220829
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: GUGGENHIME ANDREW
CENTRAL INDEX KEY: 0001230724
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39323
FILM NUMBER: 221212286
MAIL ADDRESS:
STREET 1: C/O VAXCYTE, INC.
STREET 2: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxcyte, Inc.
CENTRAL INDEX KEY: 0001649094
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 464233385
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 650-837-0111
MAIL ADDRESS:
STREET 1: 825 INDUSTRIAL ROAD, STE. 300
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: SutroVax, Inc.
DATE OF NAME CHANGE: 20150724
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-08-25
0
0001649094
Vaxcyte, Inc.
PCVX
0001230724
GUGGENHIME ANDREW
C/O VAXCYTE, INC.
825 INDUSTRIAL ROAD, STE. 300
SAN CARLOS
CA
94070
0
1
0
0
President and CFO
Common Stock
2022-08-25
4
M
0
17052
5.35
A
59239
D
Common Stock
2022-08-25
4
S
0
17052
28.00
D
42187
D
Common Stock
2022-08-26
4
M
0
1295
5.35
A
43482
D
Common Stock
2022-08-26
4
S
0
1295
28.00
D
42187
D
Common Stock
2022-08-29
4
M
0
17653
5.35
A
59840
D
Common Stock
2022-08-29
4
S
0
17653
28.00
D
42187
D
Stock Option (right to buy)
5.35
2022-08-25
4
M
0
17052
0.00
D
2030-05-11
Common Stock
17052
476566
D
Stock Option (right to buy)
5.35
2022-08-26
4
M
0
1295
0.00
D
2030-05-11
Common Stock
1295
475271
D
Stock Option (right to buy)
5.35
2022-08-29
4
M
0
17653
0.00
D
2030-05-11
Common Stock
17653
457618
D
The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.
Andrew Guggenhime, by /s/ Ron Metzger, Attorney-in-Fact
2022-08-29